PharmaShots | Incisive News in 3 Shots

Subscribe Now

Aged 6 to 11 Years

Sanofi and Regeneron Receive the US FDA's Priority Review Acceptance for Dupixent's sBLA to Treat Moderate-to-Severe Atopic Dermatitis in Children Aged 6 to 11 Years

Sanofi and Regeneron Receive the US FDA's Priority Review Acceptance for Dupixent's sBLA to Treat Moderate-to-Severe Atopic Dermat...

January 28, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us